Xenon Pharmaceuticals (XENE) Non-Current Assets (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Non-Current Assets data on file, last reported at $280.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets rose 57.63% year-over-year to $280.2 million in Q1 2026; TTM through Mar 2026 was $654.4 million, a 2.73% decrease from a year earlier, with the FY2025 full-year figure at $72.5 million, down 55.48% from the prior year.
• Non-Current Assets for Q1 2026 stood at $280.2 million, up from $72.5 million in the prior quarter.
• Over the last five years, Non-Current Assets for XENE reached as high as $319.8 million in Q4 2023 and fell as low as $12.4 million in Q1 2022.
• Historically, Non-Current Assets has averaged $154.8 million across 5 years, with a median of $155.9 million in 2024.
• Across the five-year window, Non-Current Assets surged 1475.28% in 2022 and plunged 55.48% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $153.8 million in 2022, then jumped by 107.89% to $319.8 million in 2023, then slumped by 49.08% to $162.9 million in 2024, then slumped by 55.48% to $72.5 million in 2025, then soared by 286.38% to $280.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $280.2 million in Q1 2026, $72.5 million in Q4 2025, and $127.7 million in Q3 2025.